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Abstract 
Introduction
Cancer treatments including chemotherapy and radiation 
therapy have exponentially increased the survival rate of those 
affected by malignancy. Therefore, the prominence of cognitive 
dysfunction as a result of cancer treatment, referred to as 
“chemo brain” or chemotherapy induced cognitive dysfunction 
is also increasing due to the number of cancer survivors. 
Chemotherapy induced cognitive dysfunction can have a 
negative effect on the individual’s quality of life, increase in the 
cost of care for cancer survivors and encumbrance on their 
caregivers. The purpose of this study is to establish if a 








In summary this study found
• Chemotherapy induced cognitive dysfunction is typically 
a short term rather than long term condition.
• Cognitive functions most affected are attention, 
language, memory, judgement and free recall.
• This suggests a link to frontal and medial temporal lobe 
dysfunction post chemotherapy treatment.
• This study showed no significant data to support the use 
of methylphenidate as a treatment modality for 
chemotherapy induced cognitive dysfunction.
• This study did not reveal any data to support the use of 
Gingko Biloba at 120 mg/day for the treatment or 
prevention of cognitive dysfunction post chemotherapy 
treatment.
In cancer patients, does treatment with chemotherapy 
compared to patients who do not receive chemotherapy 
treatment result in an increase in cognitive dysfunction? 
Is there a therapy available to treat post chemotherapy 
cancer treatment cognitive dysfunction for cancer survivors?
• Jansen et al. (2011) found significant decreases after receiving 
chemotherapy, followed by improvements six months after the 
completion of chemotherapy in the cognitive domains of 
visuospatial skill (p<0.001), attention (p=0.022), delayed 
memory (p=0.006), and motor function (p=0.043). These results 
suggest that chemotherapy related impairments appear to be 
acute rather than chronic.
• Lindner et al. (2014) indicated that cognitive impairments were 
found in the cross-sectional studies including immediate free 
recall (p=0.03), delayed memory (p=0.02), verbal memory 
(p<0.001), delayed recognition memory (p=0.02), selective 
attention (p=0.02), and attention capacity (p<0.001). This 
suggests that the impairments may be linked to both the frontal 
and medial temporal lobe dysfunction. Figure 1. 
• Janelsins et al. (2013) determined that there were no overall 
mean differences in cognitive function. However, subject 
analysis revealed a 61% cognitive decline in learning, attention 
and processing speed. If the pre-treatment cognitive analysis 
had not been studied, 46% of those experiencing cognitive 
decline would have been missed as their post-treatment 
assessment scores continued to be within a normal range.
• This study should increase awareness of chemotherapy 
induced cognitive dysfunction and its affect on cancer 
survivors and their families. 
• The most common areas of cognitive function affected by 
chemotherapy cancer treatment include language (verbal), 
memory, judgement and free recall.
• Educating patients of the possibility of cognitive dysfunction 
post chemotherapy cancer treatment can empower patients to 
select the best treatment options for themselves. Figure 3. 
• Early recognition and validation of cognitive dysfunction can 
reassure and comfort patients.
• Strong emotional support system during chemotherapy 
cancer treatment has been shown to have physical benefits. 
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The prominence of cognitive dysfunction because of cancer 
treatment, referred to as “chemo brain” is increasing due to the 
number of cancer survivors. Research on chemotherapy related 
cognitive dysfunction has been focused on breast cancer 
survivors. The purpose of this study was to establish if a 
connection between chemotherapy cancer treatment and 
cognitive dysfunction exists. This evaluation of literature 
explored PubMed, DynaMed, Psychiatry Online, and Cochrane 
which compared cognitive abilities before and after 
chemotherapy cancer treatment. This paper examined the 
research over the last 10 years, of women ages 18-70 and the 
connection between chemotherapy treatment and cognitive 
dysfunction. Jansen et al. (2011) found significant decreases in 
cognitive impairment after receiving chemotherapy, followed by 
improvements 6 months after the completion of chemotherapy in 
the cognitive domains of visuospatial skill (p<0.001), attention 
(p=0.022), delayed memory (p=0.006), and motor function 
(p=0.043).  Results from a study by Lindner et al. (2014) 
indicated that cognitive impairments were found in the cross-
sectional studies including immediate free recall (p=0.03), 
delayed memory (p=0.02), verbal memory (p<0.001), delayed 
recognition memory (p=0.02), selective attention (p=0.02), and 
attention capacity (p<0.001). This paper has shown that a 
positive connection between chemotherapy cancer treatment and 
cognitive dysfunction exists and that the degree of cognitive 
dysfunction is highly variable for each individual. The results 
indicated that chemotherapy related cognitive dysfunction should 
be discussed as a debilitating side effect before chemotherapy 
cancer treatment is initiated. Survivor support should also be 
increased in order to accommodate cancer survivors affected by 
chemotherapy related cognitive dysfunction. 
With the increasing numbers of cancer survivors, studies are 
needed to show if there is a positive connection between 
chemotherapy treatment and cognitive dysfunction.
• Biglia et al. (2012) suggested that chemotherapy can induce 
cognitive dysfunction, especially involving the attention 
subdomain and that psychosocial health can play a role in 
this process. Figure 2.
• Henneghan (2015) failed to show a correlation between 
modifiable environmental factors as predisposing factors for 
cognitive dysfunction post chemotherapy. However, 
psychosocial factors such as stress, isolation and lack of 
support have been associated with decrease in immediate 
memory (p<0.01), delayed memory (p<0.5), verbal fluency 
(p<0.05) and attention (p<0.01) 
• Mar Fan et al. (2007) showed no significant data to support 
the use of methylphenidate for the treatment of fatigue or 
quality of life and mood. 
• Barton et al. (2012) found that Gingko Biloba at a dose of 
120 mg/day does not present as a pharmacologic treatment 
option for women facing chemotherapy, in regard to 
preserving or enhancing cognitive function.
Figure 2. Effect of chemotherapy on cognitive function and quality of life. 
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Figure 1. 
